Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy vs Chemotherapy plus Nivolumab ± BMS-986205 in Muscle-Invasive Bladder Cancer
2024-512158-12-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised trial of nivolumab and linrodostat in bladder cancer and muscle-invasive bladder cancer (MIBC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Pathological complete response (pCR) rate of neoadjuvant chemotherapy alone, Pathological complete response (pCR) rate of neoadjuvant nivolumab plus chemotherapy and 2 more. Started Jun 2024; status: completed.
02
Drugs
nivolumablinrodostat
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2024-512158-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512158-12-00.